|
| 海曲波帕乙醇胺片联合环孢素A治疗难治性免疫性血小板减少症临床疗效及安全性观察 |
| Clinical efficacy and safety observation of the combination of Haiqubopaethanolamine tablets and cyclosporine A in the treatment of refractory immune thrombocytopenia |
| 投稿时间：2024-02-05 修订日期：2024-02-05 |
| DOI： |
| 中文关键词: 海曲波帕 环孢素 免疫性血小板减少症 疗效 安全性 |
| 英文关键词: Haiqubopa Cyclosporine Immune Thrombocytopenia Efficacy Safety |
| 基金项目: |
|
| 摘要点击次数: 555 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：观察海曲波帕乙醇胺片联合环孢素（CsA）方案治疗难治性原发免疫性血小板减少症（ITP）疗效和安全性。 方法： 选取2018年12月至2023年09月蚌埠医学院第二附属医院血液内科诊治的52例复发难治的ITP患者。选用随机数表法，将52例病例分别纳入实验组（26例）和对照组（26例），其中实验组接受海曲波帕联合环孢素的治疗方案，对照组接受地塞米松联合重组人血小板生成素（rhTPO）的治疗方案。监测两组患者经过不同方案治疗后，血小板的恢复水平、效果及安全性方面的情况。 结果：实验组总有效率73%，对照组总有效率73%，对比差异无统计学意义（P > 0.05）；实验组不良反应率35%，对照组不良反应率46%，对比差异有统计学意义（P < 0.05）。结论：海曲波帕联合环孢素的疗法安全有效，可有望成为难治的ITP患者的二线推荐治疗方案。 |
| 英文摘要: |
| Objective: To observe the efficacy and safety of combination therapy with cyclosporine (CsA) for refractory immune thrombocytopenia (ITP). Method: 52 patients with relapsed and refractory ITP admitted to our hospital from December 2018 to September 2023 were selected. According to the random number table method, the experimental group was divided into an experimental group (26 cases) and a control group (26 cases). The experimental group received a treatment plan of combination of Haiqubopa and cyclosporine, while the control group received a treatment plan of combination of dexamethasone and recombinant human thrombopoietin (rhTPO). Observe the platelet recovery level, efficacy, and adverse reactions after treatment in two groups. Result: The total effective rate of the experimental group was 73%, while that of the control group was 73%, with no statistically significant difference (P>0.05); The adverse reaction rate in the experimental group was 35%, while the adverse reaction rate in the control group was 46%, with a statistically significant difference (P<0.05). Conclusion: The combination therapy of Haiqubopa and Cyclosporine is safe and effective, and has the potential to become a second-line recommended treatment for refractory ITP patients. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
